Vivreon Biosciences, LLC has been awarded a preclinical drug discovery grant from the Alzheimer's Drug Discovery Foundation (ADDF).
"We are very pleased to announce this exciting collaboration between Vivreon Biosciences and the ADDF. The approval of this peer-reviewed grant demonstrates the quality of Vivreon Biosciences' research capabilities and commitment to find a treatment for the root cause of Alzheimer's disease," said Milton Greenberg, PhD, the principal investigator on the grant and Vice President of Drug Discovery for Vivreon Biosciences. "We will use these funds to improve our compounds with the goal of advancing them into human clinical trials."
Recent evidence suggests that chronic inflammation in the brain plays a major role in Alzheimer's initiation and pathogenesis. Vivreon joins a handful of companies attempting to target this inflammation, which is a hallmark of Alzheimer's and many other neurodegenerative diseases. Specifically, by targeting microglia, a special type of brain-resident immune cell that can become pathogenic during disease, Vivreon hopes to shut down neuroinflammation at its source, while maintaining beneficial phagocytic functions in these cells.
"The neuroinflammation program is the second largest in our research portfolio and we are excited about the potential of Vivreon's therapeutic approach," said Howard Fillit, MD, Founding Executive Director and Chief Science Officer of the ADDF.